Spero Therapeutics, Inc.
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Non-accelerated filerSmaller reporting company
State of Incorporation
DE
Business Address
675 MASSACHUSETTS AVENUE, CAMBRIDGE, MA, 02139
Mailing Address
675 MASSACHUSETTS AVENUE, CAMBRIDGE, MA, 02139
Phone
857-242-1600
Fiscal Year End
1231
EIN
000000000
Financial Overview
FY2025
$106.89M
Stockholders' Equity
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 10-K Annual financial report | March 26, 2026 | View on SEC |
| 8-K Current report of material events | March 26, 2026 | View on SEC |
| 4 Insider stock transaction report | February 9, 2026 | View on SEC |
| 4 Insider stock transaction report | February 9, 2026 | View on SEC |
| 4 Insider stock transaction report | February 5, 2026 | View on SEC |
| 4 Insider stock transaction report | February 4, 2026 | View on SEC |
| 8-K Current report of material events | January 30, 2026 | View on SEC |
| 8-K Current report of material events | December 19, 2025 | View on SEC |
| 8-K Current report of material events | November 13, 2025 | View on SEC |
| 10-Q Quarterly financial report | November 13, 2025 | View on SEC |
Annual Reports
10-K
March 26, 2026
- Strategic pivot to focus exclusively on tebipenem HBr to preserve cash.
- Cash runway extended into late 2025 through cost-cutting measures.
Insider Trading
SELL
2 insiders
7 recent transactions
View Full Insider Trading Profile
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.